Hepatic Failure Caused by Reactivation of YMDD Mutants Occurring during Preemptive Lamivudine Therapy
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Reactivation of hepatitis B virus (HBV) replication is a frequent phenomenon in patients receiving immunosuppressants or chemotherapy. It was recently reported that regional therapy, such as transarterial chemotherapy (TAC) or radiotherapy, can also induce HBV reactivation in patients with hepatocellular carcinoma (HCC), and this can be prevented by preemptive lamivudine treatment. We report an unusual case of fatal hepatitis caused by reactivation of the tyrosine-methionine-aspartate-aspartate (YMDD) lamivudine-resistant strain in a 51-year-old male patient with HCC who was receiving preemptive lamivudine therapy. This patient received combined helical tomotherapy and TAC for the treatment of HCC with pulmonary metastasis. HBV reactivation and hepatitis exacerbation occurred after 2 months of therapy, but preemptive antiviral therapy was continued. Laboratory tests showed that the serum HBV DNA level had increased by more than 10,000-fold and a severe elevation of the aminotransferase level to 1,060 U/L. Although adefovir was added to lamivudine immediately after detecting the YMDD mutants, the patient eventually died of hepatic failure. Our experience suggests that for preemptive therapy, the use of potent antiviral drugs with a low risk of drug resistance as well as close viral monitoring are important for chronic HBV carriers undergoing intensive anticancer therapy.
Abstract
Reactivation of hepatitis B virus (HBV) replication is a frequent phenomenon in patients receiving immunosuppressants or chemotherapy. It was recently reported that regional therapy, such as transarterial chemotherapy (TAC) or radiotherapy, can also induce HBV reactivation in patients with hepatocellular carcinoma (HCC), and this can be prevented by preemptive lamivudine treatment. We report an unusual case of fatal hepatitis caused by reactivation of the tyrosine-methionine-aspartate-aspartate (YMDD) lamivudine-resistant strain in a 51-year-old male patient with HCC who was receiving preemptive lamivudine therapy. This patient received combined helical tomotherapy and TAC for the treatment of HCC with pulmonary metastasis. HBV reactivation and hepatitis exacerbation occurred after 2 months of therapy, but preemptive antiviral therapy was continued. Laboratory tests showed that the serum HBV DNA level had increased by more than 10,000-fold and a severe elevation of the aminotransferase level to 1,060 U/L. Although adefovir was added to lamivudine immediately after detecting the YMDD mutants, the patient eventually died of hepatic failure. Our experience suggests that for preemptive therapy, the use of potent antiviral drugs with a low risk of drug resistance as well as close viral monitoring are important for chronic HBV carriers undergoing intensive anticancer therapy.
참고문헌 (18)
- Jang JW, "Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma", J Hepatol, 41, pp.427~435 (2004)
- Kim JH, "Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 69, pp.813~819 (2007)
- Jang JW, "A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization", Hepatology, 43, pp.233~240 (2006)
- Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy", Gastroenterology, 125, pp.1742~1749 (2003)
- Lim LL, "Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients", Aliment Pharmacol Ther, 16, pp.1939~1944 (2002)
- Lok AS, "Chronic hepatitis B", Hepatology, 45, pp.507~539 (2007)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update", Liver Int, 25, pp.472~489 (2005)
- Atkins M, "Lamivudine resistance in chronic hepatitis B", J Hepatol, 28, pp.169~ (1998)
- Jardi R, "Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants", J Virol Methods, 83, pp.181~187 (1999)
- Liaw YF, "Management of patients with chronic hepatitis B", J Gastroenterol Hepatol, 17, pp.406~408 (2002)
- Honkoop P, "Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns", J Hepatol, 26, pp.1393~1395 (1997)
- Lai CL, "A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group", N Engl J Med, 339, pp.61~68 (1998)
- Melegari M, "Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective", Hepatology, 27, pp.628~633 (1998)
- Yeo W, "Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy", Ann Oncol, 15, pp.1661~1666 (2004)
- Yeo W, "Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy", Hepatology, 43, pp.209~220 (2006)
- Chou CH, "Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells", Clin Cancer Res, 13, pp.851~857 (2007)
- Mackie TR, "Tomotherapy", Semin Radiat Oncol, 9, pp.108~117 (1999)
- Hong TS, "Megavoltage computed tomography: an emerging tool for image-guided radiotherapy", Am J Clin Oncol, 30, pp.617~623 (2007)